339 related articles for article (PubMed ID: 32828069)
21. Identification of Novel Candidate Epitopes on SARS-CoV-2 Proteins for South America: A Review of HLA Frequencies by Country.
Requena D; Médico A; Chacón RD; Ramírez M; Marín-Sánchez O
Front Immunol; 2020; 11():2008. PubMed ID: 33013857
[TBL] [Abstract][Full Text] [Related]
22. Epitope-Based Immunoinformatics Approach on Nucleocapsid Protein of Severe Acute Respiratory Syndrome-Coronavirus-2.
Rakib A; Sami SA; Islam MA; Ahmed S; Faiz FB; Khanam BH; Marma KKS; Rahman M; Uddin MMN; Nainu F; Emran TB; Simal-Gandara J
Molecules; 2020 Nov; 25(21):. PubMed ID: 33147821
[TBL] [Abstract][Full Text] [Related]
23. Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes.
Galili U
Vaccine; 2020 Sep; 38(42):6487-6499. PubMed ID: 32907757
[TBL] [Abstract][Full Text] [Related]
24. COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning.
Ong E; Wong MU; Huffman A; He Y
Front Immunol; 2020; 11():1581. PubMed ID: 32719684
[TBL] [Abstract][Full Text] [Related]
25. T and B cell Epitope analysis of SARS-CoV-2 S protein based on immunoinformatics and experimental research.
Chen Z; Ruan P; Wang L; Nie X; Ma X; Tan Y
J Cell Mol Med; 2021 Jan; 25(2):1274-1289. PubMed ID: 33325143
[TBL] [Abstract][Full Text] [Related]
26. High throughput and comprehensive approach to develop multiepitope vaccine against minacious COVID-19.
Ojha R; Gupta N; Naik B; Singh S; Verma VK; Prusty D; Prajapati VK
Eur J Pharm Sci; 2020 Aug; 151():105375. PubMed ID: 32417398
[TBL] [Abstract][Full Text] [Related]
27. Variations in SARS-CoV-2 Spike Protein Cell Epitopes and Glycosylation Profiles During Global Transmission Course of COVID-19.
Xu W; Wang M; Yu D; Zhang X
Front Immunol; 2020; 11():565278. PubMed ID: 33013929
[TBL] [Abstract][Full Text] [Related]
28. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.
Salvatori G; Luberto L; Maffei M; Aurisicchio L; Roscilli G; Palombo F; Marra E
J Transl Med; 2020 Jun; 18(1):222. PubMed ID: 32493510
[TBL] [Abstract][Full Text] [Related]
29. Revelation of Potent Epitopes Present in Unannotated ORF Antigens of SARS-CoV-2 for Epitope-Based Polyvalent Vaccine Design Using Immunoinformatics Approach.
Uttamrao PP; Sathyaseelan C; Patro LPP; Rathinavelan T
Front Immunol; 2021; 12():692937. PubMed ID: 34497604
[TBL] [Abstract][Full Text] [Related]
30. Epitopes for a 2019-nCoV vaccine.
Lucchese G
Cell Mol Immunol; 2020 May; 17(5):539-540. PubMed ID: 32094505
[No Abstract] [Full Text] [Related]
31. Energetics and IC50 based epitope screening in SARS CoV-2 (COVID 19) spike protein by immunoinformatic analysis implicating for a suitable vaccine development.
Banerjee A; Santra D; Maiti S
J Transl Med; 2020 Jul; 18(1):281. PubMed ID: 32650788
[TBL] [Abstract][Full Text] [Related]
32. Genomic evolution of severe acute respiratory syndrome Coronavirus 2 in India and vaccine impact.
Jacob JJ; Vasudevan K; Veeraraghavan B; Iyadurai R; Gunasekaran K
Indian J Med Microbiol; 2020; 38(2):210-212. PubMed ID: 32883935
[TBL] [Abstract][Full Text] [Related]
33. Exploring the SARS-CoV-2 structural proteins for multi-epitope vaccine development: an
Kumar A; Kumar P; Saumya KU; Kapuganti SK; Bhardwaj T; Giri R
Expert Rev Vaccines; 2020 Sep; 19(9):887-898. PubMed ID: 32815406
[TBL] [Abstract][Full Text] [Related]
34. Approaches and Challenges in SARS-CoV-2 Vaccine Development.
Dagotto G; Yu J; Barouch DH
Cell Host Microbe; 2020 Sep; 28(3):364-370. PubMed ID: 32798444
[TBL] [Abstract][Full Text] [Related]
35. Landscape and selection of vaccine epitopes in SARS-CoV-2.
Smith CC; Olsen KS; Gentry KM; Sambade M; Beck W; Garness J; Entwistle S; Willis C; Vensko S; Woods A; Fini M; Carpenter B; Routh E; Kodysh J; O'Donnell T; Haber C; Heiss K; Stadler V; Garrison E; Sandor AM; Ting JPY; Weiss J; Krajewski K; Grant OC; Woods RJ; Heise M; Vincent BG; Rubinsteyn A
Genome Med; 2021 Jun; 13(1):101. PubMed ID: 34127050
[TBL] [Abstract][Full Text] [Related]
36. Structure-based drug designing and immunoinformatics approach for SARS-CoV-2.
Panda PK; Arul MN; Patel P; Verma SK; Luo W; Rubahn HG; Mishra YK; Suar M; Ahuja R
Sci Adv; 2020 Jul; 6(28):eabb8097. PubMed ID: 32691011
[TBL] [Abstract][Full Text] [Related]
37. Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population.
Yi Z; Ling Y; Zhang X; Chen J; Hu K; Wang Y; Song W; Ying T; Zhang R; Lu H; Yuan Z
Emerg Microbes Infect; 2020 Dec; 9(1):1988-1996. PubMed ID: 32844713
[No Abstract] [Full Text] [Related]
38. Design of novel multiepitope constructs-based peptide vaccine against the structural S, N and M proteins of human COVID-19 using immunoinformatics analysis.
Khairkhah N; Aghasadeghi MR; Namvar A; Bolhassani A
PLoS One; 2020; 15(10):e0240577. PubMed ID: 33057358
[TBL] [Abstract][Full Text] [Related]
39. Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development.
Khalaj-Hedayati A
J Immunol Res; 2020; 2020():7201752. PubMed ID: 32695833
[TBL] [Abstract][Full Text] [Related]
40. Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome.
Crooke SN; Ovsyannikova IG; Kennedy RB; Poland GA
Sci Rep; 2020 Aug; 10(1):14179. PubMed ID: 32843695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
